Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon

Open source

DOI: 10.1080/21645515.2020.1861875
Published: 2021-02-24
Container: Human Vaccines & Immunotherapeutics
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/21645515.2020.1861875,
  title = {Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial},
  author = {Juliana Park and Sophia Archuleta and May-Lin Helen Oh and Lynette Pei-Chi Shek and Hao Wang and Matthew Bonaparte and Carina Frago and Alain Bouckenooghe and Frederique Jantet-Blaudez and Sarah Begue and Sophie Gimenez-Fourage and Anke Pagnon},
  year = {2021},
  journal = {Human Vaccines \&amp; Immunotherapeutics},
  doi = {10.1080/21645515.2020.1861875},
  url = {https://doi.org/10.1080/21645515.2020.1861875}
}

RIS

TY  - JOUR
TI  - Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
AU  - Juliana Park
AU  - Sophia Archuleta
AU  - May-Lin Helen Oh
AU  - Lynette Pei-Chi Shek
AU  - Hao Wang
AU  - Matthew Bonaparte
AU  - Carina Frago
AU  - Alain Bouckenooghe
AU  - Frederique Jantet-Blaudez
AU  - Sarah Begue
AU  - Sophie Gimenez-Fourage
AU  - Anke Pagnon
PY  - 2021
JO  - Human Vaccines &amp; Immunotherapeutics
DO  - 10.1080/21645515.2020.1861875
UR  - https://doi.org/10.1080/21645515.2020.1861875
ER  -

APA

Park, J., Archuleta, S., Oh, M. H., Shek, L. P., Wang, H., Bonaparte, M., Frago, C., Bouckenooghe, A., Jantet-Blaudez, F., Begue, S., Gimenez-Fourage, S., & Pagnon, A. (2021). Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2020.1861875

Source records

crossref · retrieved 2026-09-25T19:37:27.705Z